I. Sermet-gaudelus, M. Bianchi, M. Garabédiangarab´garabédian, R. Aris, A. Morton et al., European cystic fibrosis bone mineralisation guidelines, Journal of Cystic Fibrosis, vol.10, pp.16-23, 2011.
DOI : 10.1016/S1569-1993(11)60004-0
URL : http://doi.org/10.1016/s1569-1993(11)60004-0

I. Sermet-gaudelus, J. Souberbielle, J. Ruiz, S. Vrielynck, B. Heuillon et al., Low Bone Mineral Density in Young Children with Cystic Fibrosis, American Journal of Respiratory and Critical Care Medicine, vol.175, issue.9, pp.951-957, 2007.
DOI : 10.1164/rccm.200606-776OC

R. Aris, P. Merkel, L. Bachrach, D. Borowitz, M. Boyle et al., Guide to Bone Health and Disease in Cystic Fibrosis, The Journal of Clinical Endocrinology & Metabolism, vol.90, issue.3, pp.1888-1896, 2005.
DOI : 10.1210/jc.2004-1629

C. Haworth, Impact of cystic fibrosis on bone health, Current Opinion in Pulmonary Medicine, vol.16, issue.6, pp.616-622, 2010.
DOI : 10.1097/MCP.0b013e32833e2e94

E. Shead, C. Haworth, E. Gunn, D. Bilton, M. Scott et al., Osteoclastogenesis during Infective Exacerbations in Patients with Cystic Fibrosis, American Journal of Respiratory and Critical Care Medicine, vol.174, issue.3, pp.306-311, 2006.
DOI : 10.1164/rccm.200512-1943OC

L. Conwell and A. Chang, Bisphosphonates for osteoporosis in people with cystic fibrosis, Cochrane Database Syst Rev, vol.4, p.2010, 2012.

S. King, D. Topliss, T. Kotsimbos, I. Nyulasi, M. Bailey et al., Reduced bone density in cystic fibrosis: ??F508 mutation is an independent risk factor, European Respiratory Journal, vol.25, issue.1, pp.54-61, 2005.
DOI : 10.1183/09031936.04.00050204
URL : http://arrow.latrobe.edu.au:8080/vital/access/manager/Repository/latrobe:5063/SOURCE1

L. Henaff, C. Gimenez, A. Haÿ, E. Marty, C. Marie et al., The F508del Mutation in Cystic Fibrosis Transmembrane Conductance Regulator Gene Impacts Bone Formation, The American Journal of Pathology, vol.180, issue.5, pp.2068-2075, 2012.
DOI : 10.1016/j.ajpath.2012.01.039
URL : https://hal.archives-ouvertes.fr/inserm-00846637

A. Gimenez-maitre, L. Henaff, C. Norez, C. Guillaume, C. Ravoninjatovo et al., Deficit of osteoprotegerin release by osteoblasts from a patient with cystic fibrosis, European Respiratory Journal, vol.39, issue.3, pp.780-781, 2012.
DOI : 10.1183/09031936.00104111
URL : https://hal.archives-ouvertes.fr/inserm-00602058

M. Stalvey, K. Clines, V. Havasi, C. Mckibbin, L. Dunn et al., Osteoblast CFTR Inactivation Reduces Differentiation and Osteoprotegerin Expression in a Mouse Model of Cystic Fibrosis-Related Bone Disease, PLoS ONE, vol.349, issue.11, p.80098, 2013.
DOI : 10.1371/journal.pone.0080098.g005

R. Baron and M. Kneissel, WNT signaling in bone homeostasis and disease: from human mutations to treatments, Nature Medicine, vol.28, issue.2, pp.179-192, 2013.
DOI : 10.1016/j.bone.2009.02.012

W. Simonet, D. Lacey, C. Dunstan, M. Kelley, M. Chang et al., Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone Density, Cell, vol.89, issue.2, pp.309-319, 1997.
DOI : 10.1016/S0092-8674(00)80209-3

W. Goessling, T. North, S. Loewer, A. Lord, S. Lee et al., Genetic Interaction of PGE2 and Wnt Signaling Regulates Developmental Specification of Stem Cells and Regeneration, Cell, vol.136, issue.6, pp.1136-1147, 2009.
DOI : 10.1016/j.cell.2009.01.015

K. Blackwell, L. Raisz, and C. Pilbeam, Prostaglandins in bone: bad cop, good cop?, Trends in Endocrinology & Metabolism, vol.21, issue.5, pp.294-301, 2010.
DOI : 10.1016/j.tem.2009.12.004
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2862787

C. Xie, B. Liang, M. Xue, A. Lin, A. Loiselle et al., Rescue of Impaired Fracture Healing in COX-2???/??? Mice via Activation of Prostaglandin E2 Receptor Subtype 4, The American Journal of Pathology, vol.175, issue.2, pp.772-785, 2009.
DOI : 10.2353/ajpath.2009.081099

J. Clancy and M. Jain, Personalized Medicine in Cystic Fibrosis, American Journal of Respiratory and Critical Care Medicine, vol.186, issue.7, pp.593-597, 2012.
DOI : 10.1164/rccm.201204-0785PP